How Do Bisphosphonates Treat Osteogenesis Imperfecta?
At a Glance
Bisphosphonates treat osteogenesis imperfecta (OI) by slowing down the cells that break down bone, allowing bone-building cells to catch up. This increases bone density and strength, helping to reduce pain and the frequency of fractures in patients.
In this answer
3 sections
Managing recurrent fractures in osteogenesis imperfecta (OI) can be incredibly stressful and exhausting for both patients and their families. To help reduce the frequency of these fractures and manage pain, bisphosphonates are often used as the primary medical treatment. They work by changing the balance of how your body naturally recycles bone tissue. By slowing down the cells that break down bone, bisphosphonates allow the cells that build bone to catch up. Over time, this helps bones become thicker and denser [1][2].
How Bone Remodeling Works
Your bones are living tissues that constantly renew themselves through a process called bone remodeling. This process involves two main types of cells:
- Osteoclasts: Cells that break down and remove old bone tissue.
- Osteoblasts: Cells that build new bone tissue.
In a healthy skeleton, these cells work in perfect balance. In osteogenesis imperfecta, genetic mutations cause the body to produce faulty or insufficient type 1 collagen—the protein that gives bones their flexibility and strength [1]. As a result, the bones are fragile and break easily [1].
It is important to understand that bisphosphonates do not cure the underlying collagen defect. Instead, they work by targeting the osteoclasts [1]. The medication attaches to the bone and stops these cells from breaking down bone tissue as quickly [2]. Because the bone-building cells (osteoblasts) keep working at their normal pace, the overall amount of bone increases [1]. Adding this extra bone mass helps compensate for the faulty collagen, making the bones thicker, though they may still be more brittle than completely healthy bone.
How Bisphosphonates Are Given
While some adults may take bisphosphonates as a pill, children with OI are typically treated with intravenous (IV) infusions [2][2]. Common IV bisphosphonates used for OI include pamidronate and zoledronic acid [2].
IV infusions are usually the preferred delivery method for kids because they ensure the medicine is fully absorbed into the body and bypass the digestive system, preventing stomach upset [2]. These treatments are given at regular intervals, often every few months, depending on the specific medication, the patient’s age, and their individual needs [2].
Treatment timelines vary. In children, bisphosphonates are often given throughout their growing years. Once a child finishes growing (when their growth plates close) or when their fracture rates significantly improve, doctors may lower the dose or suggest a “drug holiday”—a planned pause in treatment [3].
Benefits and Side Effects
Clinical studies have shown that bisphosphonates consistently increase bone mineral density in both children and adults with OI [2]. While results can vary from person to person, this therapy is known to help reduce bone pain, improve mobility, and it may help decrease the incidence of fractures [1].
Short-Term Side Effects
The most common side effect when starting treatment is called an acute phase reaction [2]. This typically happens after the very first IV infusion and causes temporary flu-like symptoms, such as:
- Fever
- Muscle and joint aches
- Chills
- Fatigue
These symptoms usually go away within a day or two and are much less common with subsequent infusions [2].
Long-Term Risks and Precautions
Because bisphosphonates alter the way bone recycles itself, there are rare but serious long-term risks to be aware of:
- Hypocalcemia (low blood calcium levels): Because the drug rapidly pulls calcium into the bones, blood calcium levels can drop [2]. Patients are often prescribed calcium and Vitamin D supplements before starting therapy to prevent this [3].
- Osteonecrosis of the jaw (ONJ): A rare condition where the jaw bone fails to heal properly, usually after a major dental extraction. It is more common in adults than children [3]. Doctors typically require a dental exam and clearance before starting treatment [2].
- Atypical femoral fractures: With long-term use, unusual fractures in the thigh bone can occasionally occur due to the bone becoming overly dense and unable to repair everyday micro-damage [3].
To minimize these risks, your medical team will regularly monitor bone density, blood calcium, and Vitamin D levels, adjusting the treatment schedule as necessary [3].
Common questions in this guide
How do bisphosphonates work for osteogenesis imperfecta?
Can bisphosphonates cure osteogenesis imperfecta?
How are bisphosphonates given to children with OI?
What are the side effects of the first bisphosphonate infusion?
Why do I need a dental check-up before starting bisphosphonates?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Do I need a dental check-up and clearance before starting bisphosphonate infusions?
- 2.Are you checking my Vitamin D and calcium levels before each infusion to prevent low blood calcium?
- 3.What specific signs of an atypical fracture in the thigh should I be watching for?
- 4.How will we monitor if the treatment is working, and at what point might we consider a 'drug holiday'?
- 5.What is the standard protocol if I experience a fever or flu-like symptoms after the first infusion?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (3)
- 1
Osteogenesis imperfecta: diagnosis and treatment.
Biggin A, Munns CF
Current osteoporosis reports 2014; (12(3)):279-88 doi:10.1007/s11914-014-0225-0.
PMID: 24964776 - 2
Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K, Phillipi CA, Steiner RD, Basel D
The Cochrane database of systematic reviews 2016; (10()):CD005088 doi:10.1002/14651858.CD005088.pub4.
PMID: 27760454 - 3
Consensus guidelines on the use of bisphosphonate therapy in children and adolescents.
Simm PJ, Biggin A, Zacharin MR, et al.
Journal of paediatrics and child health 2018; (54(3)):223-233 doi:10.1111/jpc.13768.
PMID: 29504223
This page provides educational information about bisphosphonate treatment for osteogenesis imperfecta. It does not replace professional medical advice from your endocrinologist or pediatric care team.
Get notified when new evidence is published on Osteogenesis imperfecta.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.